Catalyst
Slingshot members are tracking this event:
AcelRx Pharmaceuticals' ARX-04 Phase 3 Trial Met its Primary Endpoint, Reduced Pain Intensity in ER Patients with Moderate-to-Severe Acute Pain
Do you think this event is important to the companies below? How will it affect their stock price?
Related Companies | Importance
|
Impact on Stocks
|
||||
---|---|---|---|---|---|---|
ACRX |
|
|
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 15, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Arx-04, Reduced Pain Intensity, Er Patients